Photodithazine-Mediated Antimicrobial Photodynamic Therapy: A Systematic Review of Efficacy and Applications
Abstract
Antimicrobial resistance is a critical global health issue exacerbated by biofilm-associated infections that often resist conventional therapies. Photodithazine-mediated antimicrobial photodynamic therapy (PDZ-aPDT) has emerged as a promising alternative, demonstrating a broad-spectrum antimicrobial efficacy against multidrug-resistant bacteria and fungi, including those in biofilms. This systematic review evaluates the efficacy, safety, and clinical applications of PDZ-aPDT by synthesizing evidence from preclinical and clinical studies. Databases including PubMed, Embase, Scopus, and Cochrane were systematically searched, resulting in the inclusion of 13 studies for qualitative analysis. PDZ-aPDT consistently reduced the microbial burden in various models, including oral candidiasis, denture stomatitis, acne, and infections related to medical devices. Synergistic combinations with conventional antimicrobials and adjunctive therapies (e.g., DNase I) further enhanced its effectiveness. However, the evidence base remains limited by methodological variability, small sample sizes, and short follow-up periods. Future research should focus on rigorous clinical trials with standardized protocols and extended follow-up to establish definitive efficacy and safety profiles, facilitating a broader clinical implementation in combating antimicrobial resistance.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.